hologic , inc . notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) a new platform technology to analyze images and breast density measurement . the projects were substantially completed as planned in fiscal 2007 . the deferred income tax asset relates to the tax effect of acquired net operating loss carry forwards that the company believes are realizable partially offset by acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes . acquisition of suros surgical systems , inc . on july 27 , 2006 , the company completed the acquisition of suros surgical systems , inc . ( 201csuros 201d ) , pursuant to an agreement and plan of merger dated april 17 , 2006 . the results of operations for suros have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its mammography/breast care business segment . suros , located in indianapolis , indiana , develops , manufactures and sells minimally invasive interventional breast biopsy technology and products for biopsy , tissue removal and biopsy site marking . the initial aggregate purchase price for suros of approximately $ 248100 ( subject to adjustment ) consisted of 4600 shares of hologic common stock valued at $ 106500 , cash paid of $ 139000 , and approximately $ 2600 for acquisition related fees and expenses . the company determined the fair value of the shares issued in connection with the acquisition in accordance with eitf issue no . 99-12 , determination of the measurement date for the market price of acquirer securities issued in a purchase business combination . the components and allocation of the final purchase price , consists of the following approximate amounts: .

========================================
Row 1: net tangible assets acquired as of july 27 2006, $ 13100
Row 2: in-process research and development, 4900
Row 3: developed technology and know-how, 46000
Row 4: customer relationship, 17900
Row 5: trade name, 5800
Row 6: deferred income taxes, -21300 ( 21300 )
Row 7: goodwill, 181700
Row 8: final purchase price, $ 248100
========================================

the acquisition also provides for a two-year earn out . the earn-out is payable in two annual cash installments equal to the incremental revenue growth in suros 2019 business in the two years following the closing . the company has considered the provision of eitf issue no . 95-8 , accounting for contingent consideration paid to the shareholders of and acquired enterprise in a purchase business combination , and concluded that this contingent consideration represents additional purchase price . during the fourth quarter of fiscal 2007 the company paid approximately $ 19000 to former suros shareholders for the first annual earn-out period resulting in an increase to goodwill for the same amount . the company also accrued $ 24500 for the second and final earn-out related to suros 2019 incremental revenue growth during the fourth quarter of fiscal 2008 , with an increase to goodwill , of which $ 24400 had been paid as of september 27 , 2008 . in addition to the earn-out discussed above , the company decreased goodwill in the amount of $ 1300 during the year ended september 27 , 2008 and increased goodwill in the amount of $ 210 during the year ended september 29 , 2007 . the increase in 2007 was primarily related to recording a liability of approximately $ 550 in accordance with eitf 95-3 related to the termination of certain employees who have ceased all services for the company . approximately $ 400 of this liability was paid during the year ended september 29 , 2007 and the balance was paid during fiscal 2008 . this increase was partially offset by a decrease to goodwill as a result of a change in the valuation of certain assets and liabilities acquired based on information received during the year ended september 29 , 2007 . the decrease in goodwill during 2008 was related to the reduction of an income tax liability . there have been no other material changes to purchase price allocations. .

Question: what is the estimated price of hologic common stock used in the acquisition of suros?
Program: divide(106500, 4600)
Answer: 23.15217